肿瘤细胞治疗研究
英文原题：In vivo CAR T-cell therapy: determinants of response and durability.
体内嵌合抗原受体（CAR）T细胞疗法在患者体内生成工程化淋巴细胞，绕过了白细胞分离术、体外制造，并且在许多方案中还绕过了淋巴细胞清除。
体内嵌合抗原受体（CAR）T细胞疗法在患者体内生成工程化淋巴细胞，绕过白细胞分离术、体外制造，并在许多方案中绕过淋巴细胞清除。复发或难治性多发性骨髓瘤的研究报告，在B细胞成熟抗原导向治疗后出现深度缓解，并达到可测量残留病灶阴性。由于所给予的产品是一种递送系统，细胞受到宿主环境的塑造，这可能使疗效和安全性的解读复杂化。本综述总结了临床数据，并定义了可优化以实现持久转化的应答决定因素。它聚焦于多发性骨髓瘤，因为其临床经验最为成熟，同时借鉴自身免疫应用。
In vivo chimeric antigen receptor (CAR) T-cell therapy generates engineered lymphocytes inside the patient, bypassing leukapheresis, ex vivo manufacturing and, in many programs, lymphodepletion. Studies in relapsed or refractory multiple myeloma report deep responses with measurable residual disease negativity after B-cell maturation antigen-directed treatment. Because the administered product is a delivery system, cells are shaped by the host environment, which may complicate interpretation of efficacy and safety. This Review summarizes clinical data and defines determinants of response that could be optimized for durable translation. It focuses on multiple myeloma, where clinical experience is most mature, while drawing on autoimmune applications.
MEMBER ACCOUNT
登录成功会直接打开下一页。
